US40637H1095
US40637H1095
Halozyme Therapeutics, Inc.
Loading chart...
Elevated Business & Solvency Risk
Caution: In addition to price volatility, there are balance sheet risks due to higher debt or weaker liquidity (Health Score: 45/100).
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Largely moves in line with the broader market.
Beta (Market Relation)
0.88x
DefensiveVolatility (5Y p.a.)
40.4% p.a.
5-Year HorizonMax Drawdown (5Y)
-49.1%
5-Year HorizonSharpe Ratio
0.53
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +68.5% |
| 3 Years | 41.1% | -33.9% | 1 | +43.7% |
| 5 Years | 40.4% | -49.1% | 0.53 | +24% |
| 10 Years | 42.5% | -49.1% | 0.52 | +24.6% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 1518%.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (40.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -49.1% in the extended horizon.